Dynamics of circulating tumour DNA can guide treatment decisions for improved outcomes

A phase II trial shows that the risk of cancer recurrence as reflected by circulating tumour DNA can guide a risk-adaptive treatment strategy that improves participants’ survival compared with the current standard of care. Our biological insights can be translated into clinical decision-making — challenging the conventional fixed-course, therapeutic approach. Adapting the therapeutic strategy on the basis of participants’ risk of cancer recurrence improved survival rates.